시장보고서
상품코드
1309227

세계의 분자 종양 진단 시장-산업 규모, 점유율, 동향, 경쟁, 기회 및 예측(2018-2028년)

Molecular Oncology Diagnostics Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Product Type, By Technology, By Application, By Cancer Type, By End User, By Region

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 111 Pages | 배송안내 : 2-3일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 분자 종양 진단(Molecular Oncology Diagnostics) 시장은 예측 기간인 2024년부터 2028년까지 안정된 성장을 기록할 것으로 예측됩니다.

이 배경에는 암, 심혈관 질환, 당뇨병 등 다양한 만성 질환 유병률이 상승이 있습니다. Global Cancer Observatory에 따르면 2020년 세계에서 약 19,292,789건의 신규 암 사례가 보고되었으며, 그 중 남성은 10,065,305건, 여성은 9,227,484건이었습니다. 암은 암세포의 무질서한 증식에 의해 야기되며, 그 증식은 내막과 외막으로 퍼져 갑니다. 분자 종양 진단이란 암을 진단하기 위한 검사를 말합니다. 이 검사는 유전 물질, 단백질 또는 관련 화학 물질을 확인하고 건강과 질병 정보를 제공하는 데 사용됩니다. 그러나 새로운 진단 방법과 장비 개발이 필요하며, 이는 분자 종양 진단 시장 성장을 더욱 촉진할 것으로 예상됩니다.

암 유병률 상승

암은 세계의 가장 흔한 사망 원인 중 하나입니다. 암 환자의 세계적인 증가는 분자 종양 진단 시장의 성장 요인일 전망입니다. 미국암협회에 따르면 2021년 미국에서 새롭게 암을 앓은 환자수는 180만 명, 암 사망자수는 60만 명이었습니다. 암세포 증식에 의해 의료 관계자는 암 예방과 치료를 돕는 치료법이나 진단 서비스를 개발하기 위한 연구개발 노력을 강화하고 있습니다. 미국암협회에 따르면 폐암, 전립선암, 장암, 여성 유방암은 세계적으로 상위 4종 암종을 차지하며 신규 암 증례의 43%를 차지하고 있습니다. 예를 들어 미국암협회는 2022년 미국 결장암이 106,180례, 직장암이 44,850례 새롭게 발생했다고 추정하고 있습니다. 게다가 미국 암 학회 2020년 보고서에 따르면, 전미 종합 암 네트워크(NCCN), 미국 임상 종양 학회(ASCO), 미국 병리 학회(CAP) 등 여러 전문가 단체가 바이오마커 검사나 치료 가이드라인을 수립하고 있습니다. 따라서 이러한 치료와 영상 진단은 세계의 분자 종양 진단 시장 성장을 가속하는 요인입니다.

기술 진보

첨단 기술은 유전체학 시퀀스 기술을 구성합니다. 예를 들면, 암 게놈 시퀀싱 기술 진보, 계산 해석, 종양 모형, 최신 암 연구 기관 행해지고 있는 기술 혁신이나 연구는 암이나 그 변이의 조기 발견을 촉진합니다. 예를 들어 2020년 6월 미국 식품약국(FDA)은 비소세포 폐암 환자를 검사하기 위한 돌연변이 검사인 코바스 EGFR 돌연변이 검사에 승인을 내렸습니다. 이 검사는 상피 성장 인자 수용체를 코딩하는 EGFR 유전자와 암 내성 돌연변이, 42개 돌연변이를 확인할 수 있는 실시간 검사입니다. 이 분자 검사는 미국 Roche Molecular Systems 사에 의해 개발되었습니다.

최근 개발 및 제품상시

암과 같은 생명을 위협하는 다양한 질병 치료를 위한 신규 진단 솔루션 개발 필요성이 높아지고 있기 때문에 연구개발(R&D) 실천과 활동 급속한 진보가 시장 성장을 밀어주고 있습니다. 예를 들어 2022년 8월 Guardant Health는 Guardant Reveal 검사 용도를 확대하여 조기 유방암과 폐암과 같은 잔존 병변 검출 및 재발 모니터링을 위한 액체 생검 검사를 개발했습니다. 이 검사는 현재 유방암이나 폐암 환자가 이용 가능하며 대장암(CRC)에 대해서는 조직을 사용하지 않는 유일한 검사입니다.

게다가 2021년 12월, QIAGEN은 Denovo Biopharma사와 제휴에 의해 확산성 대세포형 B세포 림프종 치료를 위한 컴패니언 진단 검사를 개발했습니다. 이 검사는 Denovo 항암제 DB102에 반응하는 Denovo 게놈 마커 1(DGM1)을 가진 사람을 확인했습니다.

사용 가능한 사용자 정의

TechSci Research는 주어진 시장 데이터를 사용하여 기업 특정 요구에 따라 사용자 정의를 제공합니다. 보고서는 다음을 사용자 정의할 수 있습니다.

기업 정보

  • 추가 시장 진출기업(최대 5사) 상세 분석과 프로파일링

목차

제1장 주요 요약

제2장 조사 방법

제3장 주요 요약

제4장 고객 의견

제5장 분자 종양 진단 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 유형별(장치, 키트 및 분석, 소프트웨어)
    • 기술별(형광 In-Situ 하이브리드화(FISH), 차세대 시퀀싱(NGS), 중합효소 연쇄반응(PCR), 면역조직화학(IHC), 유동세포계측법, 기타 기술)
    • 용도별(조사, 임상)
    • 암 유형별 {고형암(유방암, 난소암, 전립선암, 폐암, 대장암, 기타 고형암), 혈액암(림프종, 백혈병, 다발성 골수종, 기타 혈액 악성 종양)
    • 최종 사용자별(병원, 진단센터 레퍼런스랩, 제약, 바이오테크놀로지 기업, 학술기관 및 연구기관)
    • 지역별(북미, 유럽, 아시아태평양, 남미, 중동 및 아프리카)
    • 기업별(2022년)
  • 시장 맵
    • 제품 유형별
    • 기술별
    • 용도별
    • 암 유형별
    • 최종 사용자별
    • 지역별

제6장 북미 분자 종양 진단 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 유형별
    • 기술별
    • 용도별
    • 암 유형별
    • 최종 사용자별
    • 국가별
  • 북미별 분석
    • 미국
    • 캐나다
    • 멕시코

제7장 유럽 분자 종양 진단 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 유형별
    • 기술별
    • 용도별
    • 암 유형별
    • 최종 사용자별
    • 국가별
  • 유럽 국가별 분석
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인

제8장 아시아태평양 분자 종양 진단제 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 유형별
    • 기술별
    • 용도별
    • 암 유형별
    • 최종 사용자별
    • 국가별
  • 아시아태평양 국가별 분석
    • 중국
    • 일본
    • 인도
    • 한국
    • 호주

제9장 남미 분자 종양 진단 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 유형별
    • 기술별
    • 용도별
    • 암 유형별
    • 최종 사용자별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카 분자 종양 진단 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 제품 유형별
    • 기술별
    • 용도별
    • 암 유형별
    • 최종 사용자별
    • 국가별
  • MEA : 국가별 분석
    • 아랍에미리트(UAE)
    • 사우디아라비아
    • 남아프리카

제11장 시장 역학

  • 성장 촉진 요인
  • 과제

제12장 시장 동향과 발전

제13장 경쟁 구도

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials(As Reported)
  • Key Personnel
    • Sysmex Corporation
    • F. Hoffmann-La Roche Ltd.
    • Myriad Genetics, Inc.
    • HTG Molecular Diagnostics, Inc.
    • Danaher Corporation.
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
    • Agilent Technologies, Inc.
    • QIAGEN NV
    • Illumina, Inc.

제14장 전략 제안

NJH 23.08.30

Global Molecular Oncology Diagnostics Market is anticipated to witness a steady CAGR in the forecast period, 2024-2028. This can be ascribed to the rising prevalence of various chronic diseases such as cancer, cardiovascular diseases, and diabetes, among others. According to Global Cancer Observatory, in 2020, around 19,292,789 new cancer cases were reported worldwide, among which the males and females accounted for 10,065,305 and 9 227,484 cases, respectively. Cancer is caused due to uncontrolled proliferation of cancer cells that starts from the inner lining to the outer region. Molecular oncology diagnostics refers to the tests for diagnosing cancer. These tests are used to identify the genetic material, proteins, or associated chemicals and provide information on health or disease. However, there is a need for developing new diagnostic methods and instruments, which is further expected to drive the growth of the Molecular Oncology Diagnostics Market.

The growing prevalence of cancer cases, the advanced technological advancement with the highest accuracy and precision, and the growing awareness amongst the population globally are projected to propel the growth of the market. Additionally, the high cost of molecular diagnostic techniques is expected to hamper the growth of the Global Molecular Oncology Diagnostics Market in the forecast years.

Rising Prevalence of Cancer

Cancer is one of the most common causes of death in the world. The global increase in cancer cases is probably a factor in the oncology molecular diagnostics market's growth. In the United States of America in 2021, there were 1.8 million new instances of cancer and 0.6 million cancer deaths, according to the American Cancer Society. Due to the proliferation of cancerous cells, medical professionals are increasing their research and development efforts to develop treatments and diagnostics services to aid the prevention and treatment of cancer. Lung, prostate, bowel, and female breast cancer make up the top four cancer types worldwide, accounting for 43% of all new cancer cases, according to the American Cancer Society. For instance, the American Cancer Society estimates that there will be 106,180 new instances of colon cancer and 44,850 new cases of rectal cancer in the United States by the year 2022. Additionally, several professional associations, including the National Comprehensive Cancer Network (NCCN), the American Association of Clinical Oncology (ASCO), and the College of American Pathologists (CAP), have developed biomarker testing and treatment guidelines, according to the American Cancer Society's 2020 report. Therefore, their treatment or diagnostic imaging is responsible for propelling the growth of Global Molecular Oncology Diagnostic Market.

Advancement in Technology

The advanced technology constitutes the sequencing techniques of genomics. For instance, the advancement in cancer genome sequencing technology, computational analysis, tumor models, and innovation and research going on in modern cancer research institutes promote early detection of cancer and its mutation. For instance, in June 2020, the United States Food and Drug Administration (FDA) gave approval to Cobas EGFR Mutation Test, a mutation test for testing patients with non-small cell lung cancer is a real-time test that can identify cancer resistance mutations and 42 mutations in the EGFR gene, which codes for the epidermal growth factor receptor. This molecular test was developed by a US-based company, namely Roche Molecular Systems, Inc.

Recent Developments & Product Launches

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need for developing novel diagnostic solutions for the treatment of different life-threatening diseases like cancer. For instance, in August 2022, Guardant Health expanded its Guardant Reveal test usage and developed a liquid biopsy test for residual disease detection and recurrence monitoring, including early-stage breast and lung cancers. It is currently accessible to patients with breast and lung cancer and is the only tissue-free test for colorectal cancer (CRC).

Additionally, in December 2021, QIAGEN, in partnership with Denovo Biopharma, developed a companion diagnostic test for the treatment of diffuse large B-cell lymphoma. This test identified people who have the Denovo genomic marker 1 (DGM1), which responded to the Denovo cancer drug DB102.

Market Segmentation

Global Molecular Oncology Diagnostics Market can be segmented by product type, technology, application, cancer type, end user, region, and company. Based on product type, the market can be segmented into instruments, kits and assays, and software. Based on technology, the market is fragmented into fluorescence in-situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), flow cytometry, and other technologies. Based on application, the market is fragmented into Research and Clinical. Based on cancer type, the market is fragmented into solid tumors and blood cancers. Based on end users, the market is segmented into hospitals and diagnostic centers, reference laboratories, pharmaceutical and biotechnology companies, and academic and research institutes.

Advancement in Technology and Product Launch

The market players in Global Molecular Oncology Diagnostics Market are adopting various natural and modified strategies for market growth and development. For instance, a 5-year extension of their US supply agreement for the Insured ONE (FIT) fecal immunochemistry test was announced in January 2022 by Clinical Genomics, an innovator in the development of colorectal cancer testing, and Quest Diagnostics (NYSE: DGX), the world's largest provider of diagnostic information services. By delivering InSure FIT and the new InSure ONE FIT for colorectal cancer diagnostic programs, this arrangement improves an ongoing partnership. Amgen and Plexium established a multi-year partnership to find new targeted protein degradation treatments in February 2022. The multi-year partnership aids in the development of innovative molecular glue therapies by utilizing knowledge gained from Amgen's experience in creating multi-specific compounds. Furthermore, several strategies like collaboration, partnerships, mergers, acquisitions, product launches, and technology development propel the growth of Global Molecular Oncology Diagnostic Market.

Company Profiles

Sysmex Corporation, F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., HTG Molecular Diagnostics, Inc., Danaher Corporation, QIAGEN N.V., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., QIAGEN N.V., Illumina, Inc., etc. are some of the key players operating in the global molecular oncology diagnostics market.

Report Scope

In this report, Global Molecular Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Molecular Oncology Diagnostics Market, By Product Type:

  • Instruments
  • Kits and Assays
  • Software

Molecular Oncology Diagnostics Market, By Technology:

  • Fluorescence In-Situ Hybridization (FISH)
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Flow Cytometry
  • Other Technologies

Molecular Oncology Diagnostics Market, By Application:

  • Research
  • Clinical

Molecular Oncology Diagnostics Market, By Cancer Type:

  • Solid Tumor
    • Breast Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Other
  • Blood Cancers
    • Lymphoma
    • Leukemia
    • Multiple Myeloma
    • Others

Molecular Oncology Diagnostics Market, By End User:

  • Hospitals and Diagnostic Centers
  • Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes

Molecular Oncology Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Molecular Oncology Diagnostics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molecular Oncology Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Instruments, Kits and Assays, Software)
    • 5.2.2. By Technology (Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, and Other Technologies)
    • 5.2.3. By Application (Research, Clinical)
    • 5.2.4. By Cancer Type {Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors), Blood cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)}
    • 5.2.5. By End User (Hospitals and Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes)
    • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa)
    • 5.2.7. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Product Type
    • 5.3.2. By Technology
    • 5.3.3. By Application
    • 5.3.4. By Cancer Type
    • 5.3.5. By End User
    • 5.3.6. By Region

6. North America Molecular Oncology Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By Cancer Type
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Molecular Oncology Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Cancer Type
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Molecular Oncology Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Cancer Type
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Molecular Oncology Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Cancer Type
        • 6.3.3.2.5. By End User

7. Europe Molecular Oncology Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By Cancer Type
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Molecular Oncology Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Cancer Type
        • 7.3.1.2.5. By End User
    • 7.3.2. France Molecular Oncology Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Cancer Type
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Molecular Oncology Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Cancer Type
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Molecular Oncology Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Cancer Type
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Molecular Oncology Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Cancer Type
        • 7.3.5.2.5. By End User

8. Asia-Pacific Molecular Oncology Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By Cancer Type
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Molecular Oncology Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Cancer Type
        • 8.3.1.2.5. By End User
    • 8.3.2. Japan Molecular Oncology Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Cancer Type
        • 8.3.2.2.5. By End User
    • 8.3.3. India Molecular Oncology Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Cancer Type
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Molecular Oncology Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Cancer Type
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Molecular Oncology Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Cancer Type
        • 8.3.5.2.5. By End User

9. South America Molecular Oncology Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By Cancer Type
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Molecular Oncology Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Cancer Type
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Molecular Oncology Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Cancer Type
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Molecular Oncology Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Cancer Type
        • 9.3.3.2.5. By End User

10. Middle East and Africa Molecular Oncology Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By Cancer Type
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Molecular Oncology Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Cancer Type
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Molecular Oncology Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Cancer Type
        • 10.3.2.2.5. By End User
    • 10.3.3. South Africa Molecular Oncology Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Cancer Type
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
    • 13.5.1. Sysmex Corporation
    • 13.5.2. F. Hoffmann-La Roche Ltd.
    • 13.5.3. Myriad Genetics, Inc.
    • 13.5.4. HTG Molecular Diagnostics, Inc.
    • 13.5.5. Danaher Corporation.
    • 13.5.6. QIAGEN N.V.
    • 13.5.7. Bio-Rad Laboratories, Inc.
    • 13.5.8. Agilent Technologies, Inc.
    • 13.5.9. QIAGEN N.V.
    • 13.5.10. Illumina, Inc.

14. Strategic Recommendations

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제